Dr. Rama Koya, MD
What this data tells you about Dr. Koya
Dr. Rama Koya is a medical oncology specialist in Longview, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Koya performed 57,823 Medicare services across 4,776 unique beneficiaries.
Between the years covered by Open Payments, Dr. Koya received a total of $6,688 from 36 pharmaceutical and/or device companies across 100 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Koya is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Contrast dye for imaging (iodine-based) | 13,581 | $0 | $3 |
| Iron sucrose injection (Venofer) | 11,000 | $0 | $2 |
| Pembrolizumab injection (Keytruda) | 10,400 | $43 | $137 |
| Iron infusion (Feraheme) | 9,180 | $0 | $5 |
| Blood draw (venipuncture) | 2,339 | $8 | $20 |
| Complete blood count (CBC) with differential | 1,889 | $8 | $36 |
| Comprehensive metabolic blood panel | 1,625 | $10 | $64 |
| Dexamethasone injection (steroid) | 728 | $0 | $1 |
| Office visit, established patient (30-39 min) | 601 | $91 | $368 |
| Office visit, established patient (20-29 min) | 442 | $60 | $250 |
| Ferritin level test (iron stores) | 410 | $13 | $60 |
| Iron level test | 393 | $6 | $27 |
| Iron binding capacity test | 393 | $9 | $35 |
| Complete blood count (CBC), automated | 333 | $6 | $34 |
| Microscopic examination for white blood cells with manual cell count | 322 | $4 | $22 |
| Lactate dehydrogenase (enzyme) level | 268 | $6 | $31 |
| Reticulated (young) platelet measurement | 261 | $35 | $143 |
| Anti-nausea injection (Aloxi/palonosetron) | 240 | $1 | $114 |
| Immunoglobulin level test | 219 | $9 | $56 |
| Folic acid level test | 217 | $14 | $73 |
| Vitamin B-12 level test | 213 | $15 | $76 |
| Administration of chemotherapy into vein, 1 hour or less | 174 | $97 | $707 |
| Injection, carboplatin, 50 mg | 152 | $2 | $300 |
| Ct scan of chest with contrast | 129 | $51 | $821 |
| Basic metabolic blood panel | 128 | $8 | $49 |
| Thyroid stimulating hormone (TSH) test | 118 | $16 | $80 |
| Injection of additional new drug or substance into vein | 110 | $11 | $108 |
| CT scan of abdomen and pelvis with contrast | 109 | $168 | $1,067 |
| Carcinoembryonic antigen (cea) protein level | 105 | $19 | $99 |
| Office visit, established patient, complex (40-54 min) | 98 | $131 | $496 |
| Injection, zoledronic acid, 1 mg | 97 | $6 | $431 |
| Uric acid level test | 95 | $4 | $25 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 93 | $22 | $157 |
| Hospital follow-up visit, moderate complexity | 86 | $61 | $247 |
| Drug injection, under skin or into muscle | 81 | $11 | $96 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 74 | $46 | $313 |
| Magnesium level test | 68 | $7 | $29 |
| CT scan of chest, without contrast | 66 | $35 | $686 |
| Ct scan of abdomen and pelvis without contrast | 60 | $75 | $560 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 59 | $90 | $657 |
| Injection of drug or substance into vein | 56 | $28 | $247 |
| Injection, diphenhydramine hcl, up to 50 mg | 53 | $1 | $7 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 52 | $1,099 | $4,802 |
| Administration of chemotherapy into vein, each additional hour | 51 | $21 | $164 |
| Administration of additional new drug or substance into vein, 1 hour or less | 51 | $49 | $344 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 51 | $71 | $70 |
| Beta-2 microglobulin (protein) level | 46 | $16 | $96 |
| Chest X-ray, 2 views | 37 | $13 | $61 |
| New patient office visit (45-59 min) | 37 | $112 | $565 |
| Hospital follow-up visit, low complexity | 37 | $38 | $135 |
| PSA test (prostate cancer screening) | 33 | $18 | $94 |
| Blood creatinine level | 32 | $5 | $31 |
| Urea nitrogen level to assess kidney function, quantitative | 32 | $4 | $24 |
| Drawing of blood for a medical problem | 31 | $61 | $264 |
| New patient office visit, complex (60-74 min) | 30 | $159 | $709 |
| Infusion, normal saline solution , 1000 cc | 29 | $2 | $19 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 26 | $349 | $1,722 |
| Unclassified drugs | 26 | $1 | $8 |
| Initial hospital admission, moderate complexity | 24 | $100 | $470 |
| Initial hospital admission, high complexity | 24 | $133 | $694 |
| Irrigation of implanted venous access drug delivery device | 23 | $19 | $114 |
| Administration of additional new drug or substance into vein using push technique | 22 | $42 | $289 |
| Ct scan of soft tissue of neck with contrast | 21 | $51 | $658 |
| Automated urinalysis | 16 | $2 | $16 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 15 | $133 | $523 |
| Infusion into a vein for hydration, 31-60 minutes | 12 | $25 | $256 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (59%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Koya is a mixed practice specialist, with above-average Medicare volume (top 17% in TX), with consulting-driven industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Koya experienced with contrast dye for imaging (iodine-based)?
Does Dr. Koya receive payments from pharmaceutical companies?
How do Dr. Koya's costs compare to other medical oncologists in Longview?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology